Name: c-Myc Antibody EP121, also known as Y69
Description and applications: The c-MYC gene is located at chromosome 8q24. It is required for
progression through the cell cycle and promotes cellular proliferation. The t(8;14)(q24;q32) translocation and the c-MYC/immunoglobulin heavy-chain (IGH) fusion gene are not only in Burkitt lymphoma, but are also seen in diffuse large B-cell lymphoma, blastic mantle cell lymphoma and transformed follicular lymphoma. In another study on predicting c-MYC translocation in 17 cases of Burkitt lymphomas (BLs) and 19 cases of diffuse large B-cell lymphomas (DLBCLs), Ruzinova et al. reported that the sensitivity and specificity of this c-Myc antibody on identifying tumor harboring a c- MYC rearrangement reached 96% and 90% respectively. This novel c-Myc antibody is a useful tool for identifying aggressive B-cell lymphomas likely to harbor a c-MYC rearrangement, and thus warrant genetic testing. In addition to its aberrant expression in lymphomas, c-Myc amplification and overexpression are also implicated in tumor progression or prognosis in many other malignancies including pancreatic cancer, breast cancer, prostate cancer, bladder cancer and soft tissue leiomyosarcoma. By utilizing this anti-c- Myc antibody coupled with genetically defined control experiments, a recent study by Gurel et al. demonstrated the specificity of this c-Myc antibody in the staining of paraffin-embedded prostate normal and tumor tissues. Upregulation of nuclear c-Myc protein expression may be a critical oncogenic event in driving human prostate cancer initiation and progression.
Composition: Anti-human c-Myc rabbit monoclonal antibody purified from serum and prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide.
Immunogen: A synthetic peptide corresponding to residues in N-terminus of human c-Myc protein.
دیدگاهها
هیچ دیدگاهی برای این محصول نوشته نشده است.